Viral Vector Manufacturing Facility Stage 2

The NSW Government has committed to expand and operate an advanced, licenced, clinical-grade viral vector manufacturing facility. 

The facility is located in the Westmead Health and Innovation District in Western Sydney. It will have the production capacity to meet the growing demand for viral vectors for use in gene therapy research and clinical trials in Australia and internationally.

Project information

Viral vectors are a key component of many gene therapies. They are increasingly being used in therapeutic and preventative health interventions, including vaccines. NSW is a globally recognised leader in developing and delivering gene and cell therapies.

Establishing a local viral vector manufacturing industry will secure viral vector supply for Australian researchers and give patients access to groundbreaking therapies. This will improve health and help save lives.

Investment in the facility will help create jobs and opportunities for local businesses, diversify local industries, and boost Australia’s global position as an advanced manufacturing industry.

The NSW Government has committed $134.5 million to establish the facility and to manufacture viral vector products for research and clinical trials.

Benefits

The project will:

• Leverage Australia’s world leading cell and gene therapy research expertise.
• Benefit academic and clinical communities that have made significant contributions to cell and gene therapies.
• Secure viral vector supply for Australian researchers and provide faster access for patients to advanced therapies through supporting local and clinical trials.
• Create high-value, high-skilled jobs in the health and technology sectors.
• Promote opportunities for local businesses, diversify local industries, and boost Australia’s global position  within advanced manufacturing industry.
• Provide an important educational platform for researchers, attracting students and high-performance research teams.

Scope

The project includes: 

• Building a commercial grade viral vector manufacturing facility to service clinical trials (550L from 25L capacity).
• Design and fit out of facility located within Kids Research building and Innovation Centre and procurement of specialised equipment including laboratories, plant rooms, and services.